Pentoxifylline reduces chronic post-ischaemia pain by alleviating microvascular dysfunction.

Area of Science:

• Pain research
• Vascular biology
• Pharmacology

Background:

• Microvascular dysfunction and muscle ischemia contribute to cutaneous tactile allodynia in chronic post-ischaemia pain (CPIP).
• Pentoxifylline (PTX), a vasodilator and haemorrheologic agent, was investigated for its potential to alleviate allodynia in CPIP by addressing microvascular dysfunction.

Purpose of the Study:

• To assess if pentoxifylline (PTX) can relieve allodynia in chronic post-ischaemia pain (CPIP) rats.
• To determine if PTX alleviates microvascular dysfunction contributing to CPIP.

Main Methods:

• Laser Doppler flowmetry measured plantar blood flow to assess PTX effects on post-occlusive reactive hyperaemia (microvascular function).
• Von Frey testing evaluated PTX's efficacy against CPIP-induced allodynia.
• Time-course studies assessed PTX effects early (2-8 days) and late (18-25 days) post-ischaemia/reperfusion (I/R) injury.

Main Results:

• PTX (25 mg/kg) demonstrated significant anti-allodynic effects up to 21 days post-I/R injury, but was ineffective at 30 days.
• PTX significantly improved reduced reactive hyperaemia in early CPIP rats, indicating improved microvascular function.
• PTX did not affect reactive hyperaemia in late CPIP rats, as pre-drug hyperaemia was not significantly reduced in these animals.

Conclusions:

• The anti-allodynic effect of PTX in early CPIP may stem from its ability to ameliorate microvascular dysfunction.
• Poor tissue perfusion is implicated in the early stages of CPIP pain.
• These findings suggest PTX's therapeutic potential in models of complex regional pain syndrome type I, particularly in early disease stages.